Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STX209 Open Label Extension in Fragile X Syndrome
NCT01013480Phase 2Terminated
- Sponsor
- Seaside Therapeutics
- Start
- Nov 2009
- Primary completion
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of arbaclofen in Fragile X syndrome (FXS), sponsored by Seaside Therapeutics. Started Nov 2009; status: terminated.
02
Drugs
arbaclofen
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NCT01013480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01013480.